Lenvatinib for Hepatocellular Carcinoma Patients with Nonviral Infection Who Were Unlikely to Respond to Immunotherapy: A Retrospective, Comparative Study

Aim: Atezolizumab plus bevacizumab (atezo + bev) shows a good overall survival (OS) in advanced hepatocellular carcinoma (HCC) patients. However, the OS of patients with nonviral infection is quite worse than that in those with viral infection. The present study investigated the efficacy and safety...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Oncology 2021-09, Vol.99 (10), p.641-651
Hauptverfasser:	Hatanaka, Takeshi, Kakizaki, Satoru, Nagashima, Tamon, Namikawa, Masashi, Ueno, Takashi, Tojima, Hiroki, Takizawa, Daichi, Naganuma, Atsushi, Arai, Hirotaka, Harimoto, Norifumi, Shirabe, Ken, Uraoka, Toshio
Format:	Artikel
Sprache:	eng
Schlagworte:	Cancer Clinical Study Comparative analysis Drug therapy Hepatoma Immunotherapy Methods Oncology, Experimental Virus diseases
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!